Avis Biotec Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 31-07-2024
- Paid Up Capital ₹ 1.00 M
as on 31-07-2024
- Company Age 10 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.01 M
as on 31-07-2024
- Revenue 55.48%
(FY 2023)
- Profit 59.24%
(FY 2023)
- Ebitda 66.59%
(FY 2023)
- Net Worth 12.74%
(FY 2023)
- Total Assets -1.62%
(FY 2023)
About Avis Biotec
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M.
The company currently has active open charges totaling ₹1.01 M.
Monika Khurana and Gurinder Khurana serve as directors at the Company.
- CIN/LLPIN
U24232RJ2014PTC046072
- Company No.
046072
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Aug 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Jaipur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Avis Biotec Private Limited offer?
Avis Biotec Private Limited offers a wide range of products and services, including Ayurvedic & Herbal Extracts, Plant Extracts, Fruit Extracts, Nutraceuticals & Dietary Supplements, Mineral Supplement.
Who are the key members and board of directors at Avis Biotec?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Monika Khurana  | Director | 13-Aug-2014 | Current |
| Gurinder Khurana | Director | 13-Aug-2014 | Current |
Financial Performance and Corporate Structure Insights of Avis Biotec.
Avis Biotec Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 55.48% increase. The company also saw a substantial improvement in profitability, with a 59.24% increase in profit. The company's net worth Soared by an impressive increase of 12.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Avis Biotec?
In 2023, Avis Biotec had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Avis Lifecare Private Limited
Active 14 years 3 monthsMonika Khurana and Gurinder Khurana are mutual person
Avis Pharmalabs Exim Private Limited
Active 7 years 9 monthsMonika Khurana and Gurinder Khurana are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 07 Aug 2021 | ₹1.01 M | Open |
How Many Employees Work at Avis Biotec?
Avis Biotec has a workforce of 22 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Avis Biotec, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Avis Biotec's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
